Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...

Moderna has gotten torched over the last six months - since September 2024, its stock price has dropped 51.2% to $33.99 per ...

A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price ...

Moderna stock has surged more than 20% this ... Moderna (NasdaqGS:MRNA) recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments.

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine demand and pipeline uncertainty. With shares trading near 5-year lows and ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

The article " Moderna: A Generational Opportunity for Investors in 2025 " first appeared on MarketBeat.

Nasdaq provides Price/Earnings Ratio (or PE Ratio) and PEG ratio for stock evaluation. Financial analysts and individual investors use PE Ratio and PEG ratios to determine the financial ...

two purchases of Moderna’s stock by a firm controlled by MRNA CEO Stephane Bancel were reported. Bancel’s company, called Boston Biotech Ventures, bought 102,821 shares for an average price of ...